Does BlackRock own Rentokil?
BlackRock does not own Roche Holding AG, a publicly traded company with a diverse ownership base. According to recent market data, institutions collectively own approximately 36% of Roche, with BlackRock being one of these institutional stakeholders, holding about 4.2% of the shares. The company’s ownership structure is dispersed, with the general public—primarily individual investors—collectively holding a majority stake of 56%. Since no single entity maintains a majority interest, Roche functions as an independent corporation governed by its own board. BlackRock’s position is that of a fiduciary asset manager; it holds these shares on behalf of its clients rather than for its own corporate control. Consequently, BlackRock does not dictate Roche's clinical research strategies, pricing policies, or daily management, serving instead as a significant shareholder interested in the long-term value of the company.
Related FAQs
Yes, Sonic Automotive (trading under the ticker SAH) has experienced a substantial overall increase in its stock price over extended market horizons, reflecting solid financial growth as a premier automotive retailer and dealership network operato...
Repligen Corporation operates as a life sciences bioprocessing company, generating its revenue by developing, manufacturing, and commercializing highly specialized bioprocessing technologies utilized by pharmaceutical and biotechnology developers.
Andy Sieg, heading wealth management divisions at major financial institutions like Citi, commands elite executive compensation packages reflecting top-tier leadership in global wealth management.
Executive compensation for the Chief Executive Officer of Reinsurance Group of America (RGA)—a leading global life and health reinsurance enterprise—reflects institutional financial services benchmarks.
As of the close of the trading session on July 24, 2026, Revvity Inc (RVTY) stock was priced at $110.47 per share.